Business
Eli Lilly's Q4 Earnings Loom: A Buying Opportunity or a Gamble?
As Eli Lilly prepares to report its Q4 and full-year 2025 results on February 4th, investors are weighing whether the pharmaceutical giant's premium valuation leaves room for a positive surprise, or if the stock is priced for perfection.